January 2013 in “Biology of blood and marrow transplantation” The authors developed a severe mouse model of chronic graft-versus-host disease and reported that rapamycin treatment improved survival compared to placebo, potentially by promoting regulatory T cell expansion.
January 2017 in “Dermatology Review” This article discusses skin lesions in chronic graft-versus-host disease and highlights the importance of coordinated care between haematologists and dermatologists for effective management; it presents no new clinical results.
36 citations
,
March 2014 in “Annals of the Rheumatic Diseases” This study found that activating liver X receptors with an agonist reduced skin fibrosis in experimental models, particularly in inflammation-driven conditions, by inhibiting macrophage infiltration and interleukin-6 release.
January 2011 in “Junshi yixue” This study established a murine chronic graft-versus-host disease model with scleroderma features, showing typical skin changes and cellular infiltrates associated with the condition.
58 citations
,
April 2012 in “Journal of the American Academy of Dermatology” Graft-versus-host disease is a complication where donor immune cells attack the recipient's body, often affecting the skin, liver, and gastrointestinal tract.